IMMP1L: A Drug Target / Disease Biomarker (G196294)

Target Name: IMMP1L

NCBI ID: G196294

IMMP1L

IMMP1L: A Drug Target / Disease Biomarker

IMMP1L, also known as IMP1L2, is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and intestines. It is a key regulator of the immune response and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the key functions of IMMP1L is its role in the immune response. It is a critical regulator of the development and function of natural killer cells, which are a crucial part of the immune system that help to protect the body against infection and disease. IMMP1L plays a vital role in the regulation of the production and function of these cells by controlling the activity of a protein called nuclear factor of T cells (NFAT).

In addition to its role in the immune system, IMMP1L is also involved in the regulation of inflammation and fibrosis. It has been shown to play a key role in the development of fibrosis, a process that can lead to the development of cancerous tumors. In addition, IMMP1L has also been shown to contribute to inflammation in various tissues, including the lungs, heart, and kidneys.

IMMP1L has also been implicated in a number of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which can lead to the development of symptoms such as memory loss, stiffness, and difficulty with movement.

In addition to its role in the immune and inflammatory systems, IMMP1L is also involved in the regulation of cell signaling pathways. It has been shown to play a key role in the regulation of the activity of several different signaling pathways, including the TGF-β pathway and the Wnt pathway. These signaling pathways are involved in the regulation of cell growth, differentiation, and survival, and are important for the development and maintenance of tissues and organs.

Given the involvement of IMMP1L in so many different processes in the body, it is not surprising that it has been identified as a potential drug target. Many studies have shown that IMMP1L can be targeted with small molecules and other therapeutic agents, and that such targeting can have a beneficial effect on a variety of diseases. For example, several studies have shown that inhibiting the activity of IMMP1L has the potential to treat a variety of neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a drug target, IMMP1L is also an attractive biomarker for a variety of diseases. Its expression has been shown to be elevated in a variety of diseases, including cancer, neurodegenerative conditions, and autoimmune disorders. This suggests that IMMP1L may be a useful biomarker for the diagnosis and assessment of these conditions.

Overall, IMMP1L is a protein that has important roles in the immune and inflammatory systems, as well as in the regulation of cell signaling pathways. Its potential as a drug target and as a biomarker make it an attractive target for research into the treatment of a variety of diseases. Further studies are needed to fully understand the role of IMMP1L in these processes and to develop effective therapies based on its targeting.

Protein Name: Inner Mitochondrial Membrane Peptidase Subunit 1

Functions: Catalyzes the removal of transit peptides required for the targeting of proteins from the mitochondrial matrix, across the inner membrane, into the inter-membrane space. Known to process the nuclear encoded protein DIABLO

The "IMMP1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IMMP1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets